Journal of Environmental Engineering and Science - ScienceDirect,Business Directories,Company Directories

companydirectorylist.com Global Business Directories and Company Directories

Country Lists

USA Company Directories

Canada Business Lists

Australia Business Directories

France Company Lists

Italy Company Lists

Spain Company Directories

Switzerland Business Lists

Austria Company Directories

Belgium Business Directories

Hong Kong Company Lists

China Business Lists

Taiwan Company Lists

United Arab Emirates Company Directories

Industry Catalogs

USA Industry Directories

English Français Deutsch Español 日本語 한국의 繁體简体 Português Italiano Русский हिन्दी ไทย Indonesia Filipino Nederlands Dansk Svenska Norsk Ελληνικά Polska Türkçe العربية

New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early . . .
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management Additional data on the efficacy and
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 392 No 24)
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
Zimislecel is an allogeneic stem cell–derived islet-cell therapy Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed
Coadministered Cagrilintide and Semaglutide in Adults with Overweight . . .
Semaglutide at a dose of 2 4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2 4 mg has shown promising results in early-phase trials; the efficacy of the
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection . . .
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and m